bictegravir/emtricitabine/tenofovir vs ganciclovir
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of bictegravir/emtricitabine/tenofovir and ganciclovir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .
Biktarvy
Cytovene
Biktarvy is a complete HIV-1 treatment for adults and children who weigh at least 31 pounds. It combines three medicines into one tablet to help control the virus.
Ganciclovir injection is an antiviral medicine. It helps treat and prevent cytomegalovirus (CMV) infections.
Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds. It can be used if you have never taken HIV medicine before. It can also replace your current HIV medicine if your virus is under control and you have no resistance to Biktarvy's components.
This medicine treats CMV retinitis, an eye infection, in people with weak immune systems, including those with AIDS. It also prevents CMV disease in adults who have had organ transplants and are at risk for CMV.
Biktarvy contains three drugs that each block HIV in different ways. Bictegravir stops HIV from inserting its DNA into your cells. Emtricitabine and tenofovir alafenamide interfere with an enzyme HIV needs to make copies of itself.
Ganciclovir stops CMV from multiplying. It does this by blocking a key enzyme the virus needs to make copies of itself. This helps your body fight off the CMV infection.
- • Diarrhea
- • Nausea
- • Headache
- • Fever
- • Diarrhea
- • Low white blood cell count
- • Nausea
- • Anemia (low red blood cell count)
No adverse event reports.
- Cytomegalovirus Infection 1,170
- Drug Resistance 653
- Pyrexia 590
- Neutropenia 503
- Pancytopenia 503
If you have both HIV and hepatitis B, stopping Biktarvy can cause your hepatitis B to suddenly get worse. Your doctor will need to monitor your liver closely for several months after you stop taking Biktarvy. You may need to take medicine for hepatitis B.
This drug can cause serious side effects. It can lower blood cell counts, possibly leading to severe infections or bleeding. It may also harm fertility in both men and women. Ganciclovir can cause birth defects and may increase your risk of cancer. Talk to your doctor about these risks.
There is a pregnancy registry to track outcomes in women who take Biktarvy during pregnancy. Talk to your doctor about the risks and benefits of taking Biktarvy if you are pregnant or planning to become pregnant. There is not enough data to assess the risk of major birth defects.
Ganciclovir can harm your unborn baby. Do not get pregnant while taking this medicine. Talk to your doctor about birth control. Breastfeeding is not recommended while using this medicine.
Also Compare, Nearby Drugs
Compare bictegravir/emtricitabine/tenofovir with
Compare ganciclovir with
How to Read This bictegravir/emtricitabine/tenofovir vs ganciclovir Comparison
bictegravir/emtricitabine/tenofovir is classified in the Integrase Inhibitor / NRTI Combination drug class, while ganciclovir sits within the Antiviral (Nucleoside Analog) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bictegravir/emtricitabine/tenofovir has 0 submissions while ganciclovir has 3,419. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to these drugs are removed from the body by the kidneys using the same process. taking them together might slow down how quickly they are cleared from your blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for bictegravir/emtricitabine/tenofovir or ganciclovir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.